60
Participants
Start Date
May 31, 2023
Primary Completion Date
August 20, 2024
Study Completion Date
August 20, 2024
CLS-AX
CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.
Aflibercept
Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
Cumberland Valley Retina Consultants, Hagerstown
Retina Group of Washington, Fairfax
Western Carolina Retinal Associates P.A., Asheville
Georgia Retina, PC, Marietta
Southeast Retina Center, Augusta
Retina Specialty Institute, Pensacola
Retina Group of Florida, Fort Lauderdale
Retina Associates of Florida, Tampa
Florida Retina Consultants, Lakeland
Tennessee Retina PC, Nashville
Wolfe Eye Clinic, Des Moines
Illinois Retina Associates, Oak Park
Texas Retina Associates-Plano, Plano
Texas Retina Associates - Dallas, Dallas
Texas Retina Associates - Arlington, Arlington
Retina Consultants of Texas-Bellairre, Bellaire
Retina Consultants of Texas - Katy, Katy
Retina Consultants of Texas-San Antonio, San Antonio
Austin Retina, Austin
Retina Research Institute of Texas, Abilene
Associated Retina Consultants, Phoenix
Retinal Research Institute, LLC, Phoenix
Sierra Eye Associates, Reno
Retina Consultants San Diego, Poway
Retinal Consultants of Southern California, Redlands
Retina Consultants of Orange County, Fullerton
California Retina Consultants, Bakersfield
Northern California Retina Vitreous Associates Medical Group, Inc, Mountain View
Retinal Consultants Medical Group, Inc., Sacramento
Spokane Eye Clinical Research, Spokane
Vitreo-Retinal Associates, PC, Worcester
Envision Ocular LLC, Bloomfield
Lead Sponsor
Clearside Biomedical, Inc.
INDUSTRY